White DL - Search Results

1

Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.

Tavakoli Shirazi P, Eadie LN, Page EC, Heatley SL, Bruning JB, White DL. Tavakoli Shirazi P, et al. Among authors: white dl. Cancer Lett. 2021 Aug 1;512:28-37. doi: 10.1016/j.canlet.2021.04.027. Epub 2021 May 7. Cancer Lett. 2021. PMID: 33971281

2

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.

Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL. Hiwase DK, et al. Among authors: white dl. Clin Cancer Res. 2008 Jun 15;14(12):3881-8. doi: 10.1158/1078-0432.CCR-07-5095. Clin Cancer Res. 2008. PMID: 18559609 Free article.

3

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.

Eadie L, Hughes TP, White DL. Eadie L, et al. Among authors: white dl. Leukemia. 2010 Apr;24(4):855-7. doi: 10.1038/leu.2010.7. Epub 2010 Feb 11. Leukemia. 2010. PMID: 20147980 No abstract available.

4

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

Eadie LN, Saunders VA, Hughes TP, White DL. Eadie LN, et al. Among authors: white dl. Leuk Lymphoma. 2013 Mar;54(3):569-78. doi: 10.3109/10428194.2012.715345. Epub 2012 Aug 21. Leuk Lymphoma. 2013. PMID: 22845311

5

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

White DL, Eadie LN, Saunders VA, Hiwase DK, Hughes TP. White DL, et al. Leukemia. 2013 Apr;27(5):1201-4. doi: 10.1038/leu.2012.295. Epub 2012 Oct 16. Leukemia. 2013. PMID: 23164803 No abstract available.

6

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

Eadie LN, Hughes TP, White DL. Eadie LN, et al. Among authors: white dl. Clin Pharmacol Ther. 2014 Mar;95(3):294-306. doi: 10.1038/clpt.2013.208. Epub 2013 Oct 9. Clin Pharmacol Ther. 2014. PMID: 24107928 Review.

7

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

Yeung DT, Moulton DJ, Heatley SL, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mullighan CG, Hughes TP, White DL. Yeung DT, et al. Among authors: white dl. Leukemia. 2015 Jan;29(1):230-2. doi: 10.1038/leu.2014.256. Epub 2014 Sep 2. Leukemia. 2015. PMID: 25179732 No abstract available.

8

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.

Trahair TN, Lock RB, Sutton R, Sia KC, Evans K, Richmond J, Law T, Venn NC, Irving JA, Moore S, Nievergall E, Dang P, Heatley SL, White DL, Revesz T. Trahair TN, et al. Among authors: white dl. Bone Marrow Transplant. 2016 Sep;51(9):1279-82. doi: 10.1038/bmt.2016.122. Epub 2016 May 16. Bone Marrow Transplant. 2016. PMID: 27183096 No abstract available.

9

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Richmond J, Robbins A, Evans K, Beck D, Kurmasheva RT, Billups CA, Carol H, Heatley S, Sutton R, Marshall GM, White D, Pimanda J, Houghton PJ, Smith MA, Lock RB. Richmond J, et al. Cancer Res. 2016 Aug 1;76(15):4579-91. doi: 10.1158/0008-5472.CAN-16-0523. Epub 2016 Jun 14. Cancer Res. 2016. PMID: 27302164 Free PMC article.

10

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL. Eadie LN, et al. Among authors: white dl. Leukemia. 2017 Jan;31(1):75-82. doi: 10.1038/leu.2016.179. Epub 2016 Jun 24. Leukemia. 2017. PMID: 27416909

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

311 results

Search Page